Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III HATCY trial of haploidentical HSCT with ATIR101 versus post-transplant cyclophosphamide
MOH_2019-03-24_006041Phase 3Completed
- Sponsor
- Kiadis Pharma
- Start
- Jun 2018
- Modality
- Small Molecules, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS) comparing ATIR101 arm with PTCy arm (2 arms). Started Jun 2018; status: completed.
02
Drugs
ATIR101cyclophosphamide
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on MOH_2019-03-24_006041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-03-24_006041.